TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03935906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reach Pathway
Description: Trial of outreach nurse offering point-of-care Hepatitis C (HCV) testing to opiate substitution therapy patients in community pharmacies, which is hypothesised to improve number of patients tested and cured of HCV.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education-only Pathway
Description: Trial of community pharmacists advising opiate substitution therapy patients to attend a local blood-borne virus clinic to be tested for Hepatitis C by a specialist nurse, which represents the standard care pathway for HCV patients in the countries included in the study.
Study: NCT03772275

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: New york Heart Association Class II-IV
Description: New york Heart Association Class II-IV  study of markers

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: New york Heart Association Class I
Description: New york Heart Association Class I
Study: NCT01868685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338
Description: BYM338

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03403595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-EB-PSMA-617
Description: accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
Study: NCT03774511

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Interval Exercise & Moderate Intensity Interval Exercise
Description: Different Interval intensities Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Interval Exercise & Moderate Intensity Interval Exercise
Description: Different Interval intensities Exercise
Study: NCT02297074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ordinary white bread
Description: The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precooked-Frozen White Bread
Description: The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered
Study: NCT03690466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study device treatment
Description: The ultrasound portable device comprises a tabletop control unit and a transducer connected to the control unit by a cord.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device treatment
Description: A similar device as used for the study device treatment will be used, except that no energy will be delivered to the spleen.
Study: NCT02916576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood-Glucose Monitoring Systems for self-testing
Description: This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices.
Study: NCT01703598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Placement of Deep Brain Stimulation electrodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DBS surgery
Description: Placement of DBS electrodes
Study: NCT02064283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion MRI
Study: NCT02297074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candeal-flour White Bread
Description: The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alfacar White Bread
Description: The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholemeal Bread
Description: The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 50 g of glucose were administered as a reference
Study: NCT02235012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CHLORURE DE SODIUM 0,9 % MACOPHARMA :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CHLORURE DE SODIUM 0,9 % MACOPHARMA :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min
Study: NCT02263105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDDP
Study: NCT03158623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Study: NCT04062331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: By means of the magnetic stimulator we induce a cerebral electric current that is able to obtain a motor potential in the first dorsal interosseous bone of the left hand.~The intervention procedure consists of two steps: First step: Obtaining the Motor Evoked Threshold at Rest: Each patient, regardless of to the group to which they belong will have his/her threshold evoked motor calculated at rest, by stimulation of the right motor cortex, evoking electromyographic responses in the contralateral muscles. Second step: Administration of TMS: To calculate the motive threshold as the percentage of the same to which the treatment will have to be applied, a device equipped with a coil. The treatment will be administered for 5 consecutive days, with 3 weeks of rest, between each stimulation. To complete a treatment period of 14 months. The stimulation with TMS will be carried out every day in the same time slot for 5 consecutive days every 4 weeks, during a period of 14 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: By means of the magnetic stimulator we induce a cerebral electric current that is able to obtain a motor potential in the first dorsal interosseous bone of the left hand.~The intervention procedure consists of two steps: First step: Obtaining the Motor Evoked Threshold at Rest: Each patient, regardless of to the group to which they belong will have his/her threshold evoked motor calculated at rest, by stimulation of the right motor cortex, evoking electromyographic responses in the contralateral muscles. Second step: Administration of TMS: To calculate the motive threshold as the percentage of the same to which the treatment will have to be applied, a device equipped with a coil. The treatment will be administered for 5 consecutive days, with 3 weeks of rest, between each stimulation. To complete a treatment period of 14 months. The stimulation with TMS will be carried out every day in the same time slot for 5 consecutive days every 4 weeks, during a period of 14 months.
Study: NCT02263105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: If hematologic and nonhematologic toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) from the previous cycle had been grade 0 or 1, then TMZ dose escalation to was allowed to the maximum of 150 mg/m2. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity had occurred, then TMZ dose was reduced in 25 mg/m2 steps. If grade 4 nonhematologic toxicity occurred, patient treatment was halted. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity continued when TMZ dose was in the minimum of 75 mg/m2, patient treatment was halted.
Study: NCT04383392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate adaptive pacing
Description: Rate-adaptive pacing is a function of permanent pacemaker to accelerate patients' heart rate when they are walking, stair climbing, running or carrying on intensive physical activity. Appropriately, the function is similar to human's electrophysiology of sinus node but it may be difficult to replace sinus node's function totally. For example, the acceleration or deceleration slope when exercise beginning or cessation is not always the same or consistent in different patients and different time.
Study: NCT03158623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellerate
Study: NCT00872378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
Study: NCT04383392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rate adaptive pacing
Description: Rate-adaptive pacing is a function of permanent pacemaker to accelerate patients' heart rate when they are walking, stair climbing, running or carrying on intensive physical activity. Appropriately, the function is similar to human's electrophysiology of sinus node but it may be difficult to replace sinus node's function totally. For example, the acceleration or deceleration slope when exercise beginning or cessation is not always the same or consistent in different patients and different time.
Study: NCT04325425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI Protocol
Description: Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
Study: NCT02125357

Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam
Study: NCT02125357

Intervention type: DRUG
Group type: OTHER
Intervention: Enzalutamide
Description: 160mg PO OD as per standard of care.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam
Study: NCT02279849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communications
Description: Communication materials were used to promote healthier items to consumers in corner stores.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pricing
Description: The pricing incentives were used to help promote sales of healthier food items.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam
Study: NCT02279849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined (Communications & Pricing)
Description: Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
Study: NCT01567202

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination
Description: Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: blank placebo
Description: Saline that has the same appearance with DC vaccine.
Study: NCT02084680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community health workers
Description: community health workers offering individual prenatal education to pregnant women
Study: NCT03032614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin Mesylate is a synthetic halichondrin analog.
Study: NCT04062331

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administration of Transcranial Magnetic Stimulation at 0 Hz (the patient will be only under drug standar therapy)
Study: NCT03137472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
Study: NCT03358290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-051
Description: Active drug tablets containing JTE-051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-051
Description: Active drug tablets containing JTE-051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-051
Description: Active drug tablets containing JTE-051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-051
Description: Active drug tablets containing JTE-051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets identical in appearance to the active drug tablets
Study: NCT00416078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caregiver website support
Description: caregiver access to website support for 6 months embedded in one year of customary care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: caregiver brief supportive phone calls
Description: caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
Study: NCT03473808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: task-practice therapy
Description: Standardized hand therapy program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Peripheral vibration applied to the wrist skin at an imperceptible level
Study: NCT02520401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic - BioGaia
Description: Use of a probiotic tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of a placebo tablet